AOD9604 10mg

AOD9604 (Anti-Obesity Drug 9604) is the C-terminal fragment of human growth hormone — specifically amino acids 176–191 — that contains the fat-metabolizing properties of HGH without any of the anabolic, IGF-1-stimulating effects. It was originally developed by Monash University (Melbourne) in the 1990s as part of a program to isolate the lipolytic mechanism of GH from its anabolic mechanisms.

Why Fragment a Peptide?

Full-length HGH stimulates multiple receptor pathways simultaneously: it drives IGF-1 production (anabolism and potential pro-growth effects), stimulates GH receptors in liver, muscle, and bone (causing insulin resistance at high doses), and activates the 176–191 region responsible for lipolysis. By isolating just the lipolytic fragment, researchers created a compound that retains targeted fat metabolism while eliminating the side effect risks of full HGH: - No IGF-1 stimulation (no anabolic or proliferative effects) - No insulin resistance (full HGH is diabetogenic at pharmacological doses) - No bone or organ growth effects - FDA Investigational New Drug status granted; GRAS (Generally Recognized as Safe) designation received

Mechanism: The GH Lipolytic Fragment

The 176–191 fragment interacts with a receptor mechanism distinct from the full GH receptor. It appears to stimulate: 1. Lipolysis: Activation of hormone-sensitive lipase (HSL) in adipocytes, releasing stored triglycerides as free fatty acids for beta-oxidation 2. Anti-lipogenic effect: Inhibition of lipogenic enzymes (particularly fatty acid synthase and acetyl-CoA carboxylase), reducing new fat storage 3. Beta-3 adrenoceptor stimulation: May activate beta-3 adrenoceptors on adipocytes, which drives thermogenesis and further lipolysis — the same receptor targeted by fat-burning compounds in brown adipose tissue

These effects are particularly active on visceral fat deposits, which express higher concentrations of the relevant receptors.

Clinical History and Safety Profile

AOD9604 has been through extensive preclinical and clinical evaluation: - Phase 1 and Phase 2a trials conducted in Australia and the US - Phase 2b trial showed modest but consistent fat loss improvements vs. placebo - FDA GRAS status granted — among the most favorable regulatory classifications for a research peptide - No adverse signals on insulin sensitivity, blood glucose, IGF-1 levels, or cardiovascular markers across all trials - No anabolic effects observed at any tested dose

The Practical Case for AOD9604

AOD9604's value proposition is its safety profile and mechanism specificity: - Users who want GH-mediated lipolytic effects without committing to full GH peptide protocols - Individuals where IGF-1 elevation is undesired (certain medical contexts) - Stack addition for fat loss protocols alongside GLP-1 agents or Ipamorelin/CJC - Morning fasted injection takes advantage of low insulin, maximizing the lipolytic response

The fat loss magnitude from AOD9604 alone is modest relative to GLP-1 agents — its strength is as a targeted adjunct in comprehensive body composition protocols, not a standalone weight loss solution.